$17.19
-0.17 (-0.98%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where OMER is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
24 interventional · 1 expanded access · 9 with posted results
Held by 9 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Ancora Advisors LLC, CITADEL ADVISORS LLC, +4 more) · FINRA short interest 9.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaNCT06298955To assess overall safety and tolerability of OMS906 administration at 8-week intervals in PNH patients.Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: OMS906 study drug | Paroxysmal Nocturnal Hemoglobinuria | 25 | Dec 2026 | ≤ 134 d | 2026-07-16 |
| Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNNCT06209736To assess OMS906 5mg/kg IV administration at 4-week intervals in patients with C3G and ICGN.Open-label · Treatment | Phase 2 | Recruiting | Drug: OMS906 study drug | C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis | 20 | Jan 2026 | — | 2025-07-15 |
| Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMANCT05855083100-day survival rate following high-risk HSCT-TMA diagnosis.Open-label · Treatment | Phase 2 | Recruiting | Drug: Biological: narsoplimab | Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation | 18 | Dec 2025 | — | 2025-03-25 |
| Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal HemoglobinuriaNCT05889299To Assess the Overall Safety and Tolerability of Zaltenibart (OMS906) Administration in PNH patientsOpen-label · Treatment | Phase 1 | Completed | Biological: OMS906 | Paroxysmal Nocturnal Hemoglobinuria | 15 | 2025-11-03actual | — | 2026-05-11 |
| Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabNCT05972967To assess the overall OMS906 administration at 8-week intervals in PNH patients.Non-randomized · Open-label · Treatment | Phase 2 | Completed | Biological: OMS906 | Paroxysmal Nocturnal Hemoglobinuria | 12 | 2024-10-10actual | — | 2025-10-01 |
| Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyNCT03608033results2025-12-09Percent Change in 24-hour UPE in g/Day Compared to BaselineRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: IA did not meet the prespecified primary endpoint. | Biological: OMS721 · Other: Vehicle (D5W or saline) | IgA Nephropathy | 360 | 2024-01-12actual | — | 2025-12-09 |
| Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeNCT03205995results2025-12-10Platelet Count (10^9 Platelets/L) Change From Baseline at Week 26Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor terminated study | Biological: OMS721 (narsoplimab) | Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | 6 | 2021-02-02actual | — | 2025-12-10 |
| Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721NCT02682407results2026-03-30Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE).Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study terminated by Sponsor | Biological: OMS721 (narsoplimab) | IgAN, LN, MN, C3G | 31 | 2020-08-25actual | — | 2026-03-30 |
| Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesNCT02222545results2024-08-28Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMANon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: OMS721 | Thrombotic Microangiopathies | 58 | 2020-01-30actual | — | 2024-08-28 |
| A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens ReplacementNCT02132312results2021-07-22Intraoperative Pupil DiameterRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: OMS302, Phenylephrine HCl | Unilateral Cataract Extraction, Congenital Cataract | 78 | 2016-09-12actual | — | 2021-07-22 |
| Safety and Efficacy of OMS643762 in Subjects With Huntington's DiseaseNCT02074410Assess the Safety of OMS643762Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision - pending further analysis of available data | Drug: OMS643762, Placebo | Huntington's Disease | 22 | 2014-10-15actual | — | 2018-10-22 |
| Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement SurgeryNCT02093689results2018-03-13Change in Pupil DiameterNon-randomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Pupil measurement methodology determined not appropriate in this population. | Drug: Part 1 OMS302, Part 2 OMS302, Part 2 Placebo | Intraocular Lens Replacement, Intraoperative Floppy Iris Syndrome | 18 | Aug 2014actual | — | 2018-03-13 |
| Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia SubjectsNCT01952132SafetyRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: OMS643762, Placebo | Schizophrenia | 40 | Apr 2014actual | — | 2018-10-22 |
| Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic MeniscectomyNCT01406561KOOS Symptoms SubscaleRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: OMS103HP-S, Vehicle | Meniscal Tear | 344 | Nov 2012actual | — | 2018-10-26 |
| Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationNCT01579565results2014-08-22Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter (mm) During SurgeryRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: OMS302, Placebo | Intraocular Lens Replacement | 416 | Nov 2012actual | — | 2017-06-14 |
| Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationNCT01454063results2014-08-21Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm) During SurgeryRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: OMS302, Placebo | Intraocular Lens Replacement | 405 | Mar 2012actual | — | 2014-08-21 |
| Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)NCT01193127results2014-08-28Pupil Diameter (mm) During SurgeryRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: OMS302 Solution, OMS302 Mydriatic Solution, OMS302 Anti-inflammatory Solution, Balanced Salt Solution (BSS) Solution | Cataract | 223 | Jan 2011actual | — | 2014-08-28 |
| Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract StonesNCT00857090Peak systemic exposure.Randomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: OMS201, Vehicle | Urinary Calculi, Urinary Stones, Urinary Tract Stones, Renal Calculi, Kidney Stones | 18 | Dec 2010actual | — | 2012-10-12 |
| Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) ReconstructionNCT00226759Improvement in knee functionRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: OMS103HP, Vehicle | Knee Injuries | 321 | Sep 2010actual | — | 2012-10-12 |
| Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) ReconstructionNCT00226772Improvement in knee functionRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: OMS103HP, Vehicle | Knee Injuries | 326 | Sep 2010actual | — | 2012-10-12 |
| Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) ReconstructionNCT00245271The overall incidence of adverse events regardless of relationship to study drug.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: OMS103HP, Vehicle | Anterior Cruciate Ligament Reconstruction | 480 | Mar 2010actual | — | 2011-06-27 |
| Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing MeniscectomyNCT00624845The primary efficacy endpoint is the mean VAS at 24 hours postoperatively.Randomized · Quadruple-masked · Treatment | Phase 2/3 | Completed | Drug: OMS103HP, Vehicle | Postoperative Pain | 200 | May 2009actual | — | 2011-06-27 |
| Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.NCT00721695Pupil diameterRandomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: OMS302, OMS302-PE, Vehicle | Cataract Extraction | 60 | Feb 2009actual | — | 2014-07-18 |
| Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located StonesNCT00599664PharmacokineticRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: OMS201, Vehicle | Urinary Calculi, Urinary Stones, Urinary Tract Stones | 11 | — | — | 2010-04-30 |
| Single Patient Expanded Access Treatment Plan For The Investigational Product NarsoplimabNCT04247906expanded access | — | Approved for marketing | Drug: Narsoplimab | Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA) | — | — | — | 2026-03-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19